CONCLUSIONS : Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride .
O O O O O B-DiseaseOrPhenotypicFeature I-DiseaseOrPhenotypicFeature I-DiseaseOrPhenotypicFeature O B-ChemicalEntity O B-ChemicalEntity O O O O O O B-DiseaseOrPhenotypicFeature O O O B-ChemicalEntity O B-ChemicalEntity O